Keywords emboli-protected device, carotid artery stenosis, carotid artery stenting Paraskevas et al 1 reviewed how to deal with appropriate asymptomatic patient selection for carotid revascularization procedures. Although, annual stroke rate is about 3.5% to 5% of asymptomatic patients with carotid stenosis >80%, it can range from <1 and >10% according to the presence of several criteria (eg, comorbid disease, severity of stenosis, a history of contralateral stroke, or transient ischemic attack episodes) and a number of plaque features in imaging modalities. 
The efficacy and safety of carotid artery stenting (CAS) and carotid endarterectomy (CEA) compared with medical treatment in patients with asymptomatic carotid stenosis are still controversial. The Asymptomatic Carotid Atherosclerosis and Asymptomatic Carotid Stenosis Trial have revealed that CEA has an absolute risk reduction of 5% to 6% in the net 5-year stroke risk of asymptomatic carotid stenosis compared with medical therapy (aspirin alone). 3 Nonetheless, the definition of best medical therapy (BMT), which includes antiplatelet therapy with aspirin and clopidogrel, statins, smoking cessation, optimal antihypertensive agents, strict diabetes control, and lifestyle measures have improved; this challenges the validity of these trials. 4 Carotid artery stenting is a relatively newly developed technique that includes various instruments (open or closed cell stents and protection device as well as special wires and catheters) as an alternative to CEA for carotid revascularization. The 2 large randomized "SAPPHIRE and CREST" trials nearly resulted in similar rates of ipsilateral stroke and death rates between CEA and CAS in symptomatic carotid stenosis. 3 However, CAS was related to periprocedural complications, in particular in those older than 75 years. 3 Embolic protection devices (EPDs), including distal or proximal filter and balloon occlusion system, were designed to reduce the potential for displacing embolic material especially after pre/postballoon dilatation to decrease the periprocedural period complications during CAS.
The use of an EPD was independently associated with a lower risk of stroke or death. 5 Current guidelines recommend that EPD should be considered (as class 2a-C) in CAS, although the use of EPD was inadequate in previous trials (eg, EPD sporadically used in "CREST," used only in 27% of participants in "SPACE" and not used in "CAVATAS," etc). 3 Routine EPD use may improve long-term outcomes by reducing periprocedural complication rates.
Distal EPD are commonly used in clinical practice, possibly owing to being relatively familiar to operators; it allows maintaining cerebral perfusion compared with proximal EPD during the procedure.
6-7 Distal EPD may not prevent distal embolization of minor microparticles in particular thrombotic vulnerable plaques. 6 Actually, proximal EPD has a similar principle as CEA and interrupts flow into the ipsilateral common carotid artery and external carotid artery; internal carotid artery flow is maintained by retrograde flow during CAS. 7 Although intolerance to flow cessation in use of proximal EPD may sometimes occur, it is more successful to prevent the embolization than distal EPD and was preferred for patients with high-risk plaques (recently symptomatic, ulcerated, heterogeneous, lipid rich or in the presence of intraplaque hemorrhage and intraluminal thrombus). [6] [7] In conclusion, while appropriate patient selection criteria are important for carotid revascularization procedures, using EPD may address the confusion regarding periprocedural complications and also help patients with asymptomatic carotid stenosis not to be deprived of CAS.
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